Germline testing for inherited risk of myeloid blood cancers
MyeloGen: Germline Testing for Predisposition to Myeloid Malignancies
This research will test whether a germline genetic test (MyeloGen Gene Panel) can find inherited changes linked to myeloid blood cancers in adults who have been diagnosed.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Dana-Farber Cancer Institute Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Trial ID | NCT07112287 on ClinicalTrials.gov |
What this trial studies
This prospective, single-arm study will enroll about 200 adults with histologically confirmed myeloid malignancies or recent bone marrow failure to undergo germline testing using the investigational MyeloGen Gene Panel. Study procedures include eligibility screening, in‑clinic visits, questionnaires, and a punch skin biopsy to obtain germline DNA. The protocol aims to determine how feasible it is to incorporate routine germline testing into clinical care for people with blood cancers regardless of their personal or family history. The Broad Clinical Laboratory sponsors the testing and the trial is conducted at Dana‑Farber Cancer Institute.
Who should consider this trial
Good fit: Adults 18 years or older with a confirmed myeloid malignancy or bone marrow failure within the prior 6 months who can provide consent in English and can safely undergo a skin biopsy are the intended participants.
Not a fit: People who have already had germline genetic testing for myeloid predisposition or who cannot safely undergo a skin biopsy are unlikely to receive additional benefit from participation.
Why it matters
Potential benefit: If successful, routine germline testing could identify inherited risk factors that help guide treatment decisions, transplant donor selection, and cascade testing of family members.
How similar studies have performed: Previous targeted germline panels have identified hereditary predisposition in subsets of patients with myeloid malignancies, though broad routine implementation is still being studied.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age of 18 years or older * Participants must have histologically confirmed myeloid malignancy OR bone marrow failure within the last 6 months prior to screening. * Ability to understand and provide a signed and completed consent document in English. Exclusion Criteria: * Participants who cannot safely undergo clinically indicated skin biopsy as adjudicated by the study team. * Participants who have previously undergone germline genetic testing for predisposition to myeloid malignancies
Where this trial is running
Boston, Massachusetts
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States (Recruiting)
Study contacts
- Principal investigator: Christopher R Reilly, MD — Dana-Farber Cancer Institute
- Study coordinator: Christopher R Reilly, MD
- Email: Christopherr_reilly@dfci.harvard.edu
- Phone: 407-443-6243
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.